Associated Papers
Concurrent genomic assessment of circulating tumour cells and ctDNA to guide therapy in metastatic breast cancer.
Allsopp RC et al.
Bmc Cancer, 2025
Molecular substratification of endometrial carcinomas with no special molecular profile (NSMP) by using a limited NGS custom panel may facilitate effective patient selection for the PIK3CA-targeted therapy.
Ondič O et al.
Virchows Archiv : an International Journal of Pathology, 2025
PIK3CA Mutations and Co-Mutations in Operated Non-Small Cell Lung Carcinoma.
Cokpinar S et al.
Journal of Clinical Medicine, 2024
Alpelisib for PIK3CA-mutated advanced gynecological cancers: First clues of clinical activity.
Passarelli A et al.
Gynecologic Oncology, 2024
AutoEpiCollect, a Novel Machine Learning-Based GUI Software for Vaccine Design: Application to Pan-Cancer Vaccine Design Targeting PIK3CA Neoantigens.
Samudrala M et al.
Bioengineering (basel, Switzerland), 2024
Oncogenic activation revealed by FGFR2 genetic alterations in intrahepatic cholangiocarcinomas.
Pu X et al.
Cell & Bioscience, 2023
Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial.
Napolitano S et al.
Jama Oncology, 2023
Clinical utility of Todai OncoPanel in the setting of approved comprehensive cancer genomic profiling tests in Japan.
Kage H et al.
Cancer Science, 2023
Uterine lavage identifies cancer mutations and increased TP53 somatic mutation burden in individuals with ovarian cancer.
Ghezelayagh TS et al.
Cancer Research Communications, 2022
Genetic landscape of colorectal cancer patients manifesting tumor shrinkage during SARS-Cov-2 infection.
Ottaiano A et al.
Therapeutic Advances in Medical Oncology, 2022
Evaluation of the Mutation Profile via Next-Generation Sequencing in a Turkish Population With Non-small Cell Lung Cancer.
Kahraman Çetin N et al.
Balkan Medical Journal, 2021
Spatially interacting phosphorylation sites and mutations in cancer.
Huang KL et al.
Nature Communications, 2021
Somatic Evolution in Non-neoplastic IBD-Affected Colon.
Olafsson S et al.
Cell, 2020
Clinicopathological and biological analysis of PIK3CA mutation and amplification in cervical carcinomas.
Razia S et al.
Experimental and Therapeutic Medicine, 2019
Analysis of error profiles in deep next-generation sequencing data.
Ma X et al.
Genome Biology, 2019
Dynamics of multiple resistance mechanisms in plasma DNA during EGFR-targeted therapies in non-small cell lung cancer.
Tsui DWY et al.
Embo Molecular Medicine, 2018
Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.
Juric D et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2018
Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients.
Chen L et al.
Nature Communications, 2018
First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas.
Patnaik A et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2016
PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers.
Castaneda CA et al.
Hematology/oncology and Stem Cell Therapy, 2014
Oncogenic PIK3CA mutations in colorectal cancers and polyps.
Whitehall VL et al.
International Journal of Cancer, 2012
PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups.
Cizkova M et al.
Breast Cancer Research : Bcr, 2012
Predicting the functional impact of protein mutations: application to cancer genomics.
Reva B et al.
Nucleic Acids Research, 2011
PIK3CA mutations predict local recurrences in rectal cancer patients.
He Y et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2009
Oncogenic mutation of PIK3CA in small cell lung carcinoma: a potential therapeutic target pathway for chemotherapy-resistant lung cancer.
Shibata T et al.
Cancer Letters, 2009
PIK3CA gene mutations in endometrial carcinoma: correlation with PTEN and K-RAS alterations.
Velasco A et al.
Human Pathology, 2006
High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma.
Oda K et al.
Cancer Research, 2005